I think when you consider a similar small biotech such as Clinuvel (cuv) market cap $1.3 billion you can get an insight into ANPs potential future. Both companies targeted rare diseases in order to get the drugs approved. CUVs drug is approved by EMA and FDA and they are currently looking at further indications. Their drug treats EPP which is not as prevalent as DMD. It's a possible model that ANP may emulate. As many others have stated DMD is the gateway. From there, more mainstream/wide spread diseases could potentially be targeted.
ANP at a market cap a bit over 100 million dollars looks incredibly cheap just for DMD let alone any further uses for the drug.
- Forums
- Charts
- Chart
I think when you consider a similar small biotech such as...
-
- There are more pages in this discussion • 2,475 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.1¢ |
Change
-0.002(2.41%) |
Mkt cap ! $75.72M |
Open | High | Low | Value | Volume |
8.4¢ | 8.4¢ | 8.1¢ | $36.29K | 444.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 106250 | 8.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.2¢ | 38888 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 106250 | 0.080 |
3 | 132078 | 0.079 |
2 | 120924 | 0.078 |
2 | 46800 | 0.075 |
1 | 100000 | 0.074 |
Price($) | Vol. | No. |
---|---|---|
0.082 | 38888 | 1 |
0.083 | 59708 | 2 |
0.085 | 136669 | 3 |
0.086 | 27375 | 1 |
0.087 | 531562 | 3 |
Last trade - 11.23am 04/09/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |